Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Invested Capital: 2021-2022

Historic Invested Capital for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $114.1 million.

  • Cardiol Therapeutics' Invested Capital rose 59.95% to $114.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $114.1 million, marking a year-over-year increase of 59.95%. This contributed to the annual value of $64.8 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Cardiol Therapeutics reported Invested Capital of $114.1 million as of Q3 2022, which was down 0.87% from $115.1 million recorded in Q2 2022.
  • Cardiol Therapeutics' Invested Capital's 5-year high stood at $143,052.4 billion during Q1 2022, with a 5-year trough of $53.5 million in Q1 2021.
  • For the 2-year period, Cardiol Therapeutics' Invested Capital averaged around $20,436.1 billion, with its median value being $71.4 million (2021).
  • Data for Cardiol Therapeutics' Invested Capital shows a peak YoY surged of 267,226,100.77% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Cardiol Therapeutics' Invested Capital stood at $64.4 million in 2021, then spiked by 59.95% to $114.1 million in 2022.
  • Its last three reported values are $114.1 million in Q3 2022, $115.1 million for Q2 2022, and $143,052.4 billion during Q1 2022.